A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

Sponsor
Cantex

Protocol Number
CAN-201

To Learn More Call
201-510-0910

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Eisai

Protocol Number
E7777-G000-302

To Learn More Call
201-510-0910

“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-568

To Learn More Call
201-510-0910

Optimizing Personalized Care Using Economic Studies of Genomic Testing

Site
Hackensack

Sponsor
Georgetown

Protocol Number
Georgetown U01 COTA Database

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a

Sponsor
Bayer

Protocol Number
Bayer 16044

To Learn More Call
201-510-0910

A Phase I, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult patients with advanced malignancies

Sponsor
Seattle Genetics

Protocol Number
Seattle Genetics SGNS40-001

To Learn More Call
201-510-0910

Pilot Study Analyzing Blood Samples for Steroid Responsiveness using F-DEX Binding Assay

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC PRO 00006200 (Pilot Study-Pediatricts)

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease